ONTARIO, Calif., Feb. 4, 2004 (PRIMEZONE) -- LifePoint, Inc. (AMEX:LFP), announced that in conjunction with the Company's fiscal 2004 third quarter earnings release, you are invited to listen to its conference call on Wednesday, February 11, 2004 at 4:30 p.m., EST (1:30 p.m. PST), with Linda H. Masterson, President and CEO and Craig S. Montesanti, Vice President Finance and Chief Accounting Officer.
What: LifePoint, Inc.'s Fiscal 2004 Third Quarter Conference Call When: Wednesday, February 11, 2004 at 4:30 p.m., EST Web address: http://www.streetevents.com, http://www.companyboardroom.com, or http://www.LifePointInc.com Dial-in numbers: 1-800-299-7635 and 1-617-786-2901 (international), Passcode #36893261.
If you are unable to participate, an audio digital replay of the call will be available from February 11, 2004 at 6:30 p.m. EST until 6:30 p.m. EST, March 11, 2004, by dialing 1-888-286-8010 (domestic) or 617-801-6888 (international) using confirmation code #54967588. A web archive will be available for 30 days at http://www.streetevents.com, http://www.companyboardroom.com , or http://www.LifePointInc.com. The company will issue its quarterly letter to shareholders following the conference call.
About LifePoint, Inc
LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT(r) Test System - a rapid diagnostic testing, screening and drug monitoring device for use in law enforcement and the workplace, and in the future, ambulances, pharmacies, and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, have allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol. The initial three target markets - law enforcement, industrial workplace and medical emergency room - are estimated to be over $1.6 billion in total opportunity.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. Although the Company believes that the expectations reflected in any forward-looking statements made herein are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company undertakes no obligation to update any forward-looking statements made to conform to actual results or to changes to expectations. These risks include, but are not limited to the need to hire personnel, dependence on third parties for certain marketing efforts, FDA 510(k) clearance in medical markets, market acceptance and potential need for additional financing. These risks and others are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
LifePoint(r) and IMPACT(r) are trademarks of LifePoint, Inc.